The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.

Mark AyoubCarol FarisTajana JuranovicHarleen ChelaEbubekir Daglilar

Published in: Cancers (2024)

The use of GLP-1 RAs in patients with type 2 diabetes mellitus (T2DM) does not appear to substantially elevate the risk of pancreatic cancer; in fact, it may potentially exert a protective effect.

Keyphrases

type diabetes
wild type
metabolic syndrome
adipose tissue
weight loss